Recent advances in genome-wide single-nucleotide polymorphism (SNP) analyses have revealed previously unrecognized microdeletions and uniparental disomy (UPD) in a broad spectrum of human cancers. As acute myeloid leukemia (AML) represents a genetically heterogeneous disease, this technology might prove helpful, especially for cytogenetically normal AML (CN-AML) cases. Thus, we performed highresolution SNP analyses in 157 adult cases of CN-AML. Regions of acquired UPDs were identified in 12% of cases and in the most frequently affected chromosomes, 6p, 11p and 13q. Notably, acquired UPD was invariably associated with mutations in nucleophosmin 1 (NPM1) or CCAAT/enhancer binding protein-a (CEBPA) that impair hematopoietic differentiation (P ¼ 0.008), suggesting that UPDs may preferentially target genes that are essential for proliferation and survival of hematopoietic progenitors. Acquired copy number alterations (CNAs) were detected in 49% of cases with losses found in two or more cases affecting, for example, chromosome bands 3p13-p14.1 and 12p13. Furthermore, we identified two cases with a cryptic t(6;11) as well as several non-recurrent aberrations pointing to leukemia-relevant regions. With regard to clinical outcome, there seemed to be an association between UPD 11p and UPD 13q cases with overall survival. These data show the potential of high-resolution SNP analysis for identifying genomic regions of potential pathogenic and clinical relevance in AML.
Introduction
Acute myeloid leukemia (AML) is a genetically heterogeneous clonal disorder characterized by the accumulation of acquired somatic genetic alterations in hematopoietic progenitor cells that alter normal mechanisms of self-renewal, proliferation and differentiation. 1 Approximately 45% of adult AML cases lack microscopically visible chromosomal abnormalities (cytogenetically normal AML (CN-AML)). 2, 3 However, somatically acquired mutations have been identified in several genes in CN-AML: the nucleophosmin 1 (NPM1) gene, the fms-related tyrosine kinase 3 (FLT3) gene the CCAAT/enhancer binding protein-a (CEBPA) gene, the myeloid-lymphoid or mixed-lineage leukemia (MLL) gene, the neuroblastoma RAS viral oncogene homolog (NRAS) gene, the Wilms' tumor 1 (WT1) gene, and the runt-related transcription factor 1 (RUNX1) gene. 4, 5 These aberrations underscore the genetic complexity of CN-AML and many additional genetic lesions are expected to be present in this subset of AML.
With the advent of genome-wide single-nucleotide polymorphism (SNP)-based microarrays providing both copy number and allele-specific information, it has now become possible to search the genome for subtle copy number alterations (CNAs) and regions with loss of heterozygosity. 6, 7 For example, arraybased SNP analysis has proved valuable for the identification of novel genetic lesions in acute lymphoblastic leukemia 8, 9 and various types of solid tumors. 10 In AML, a first study by Raghavan et al. 11 and a recent large study by Gupta et al.
12
using low-resolution SNP microarrays with 10 000 probe sets (10 k) identified uniparental disomy (UPD), resulting in loss of heterozygosity in 19% of newly diagnosed CN-AML 11 and 17% of unselected AML cases. 12 Uniparental disomy is caused by chromosomal non-disjunction or by homologous recombination during mitosis leading to partial duplication of the maternal or the paternal chromosome. UPDs are thought to contribute to leukemogenesis by causing homozygosity of gene mutations located in the respective genomic regions, or by duplication of a chromosomal segment harboring imprinted genes. For example, UPDs on chromosome arms 11p, 13q and 19q have been shown to be associated with homozygous WT1, FLT3 internal tandem duplications (ITD) and CEBPA mutations, respectively. 12, 13 In addition to regions of UPD, studies in AML and myelodysplastic syndrome have also revealed cryptic CNAs; however, thus far no novel recurrent abnormalities have been identified. 14, 15 In this study we have used high-resolution SNP microarrays to detect regions of UPD and acquired genomic imbalances in paired leukemia and germline DNA samples from 157 CN-AML cases to delineate novel candidate disease genes.
Materials and methods

Patient samples
Diagnostic and remission samples from 157 younger adult patients with CN-AML enrolled on two German-Austrian AML Study Group (AMLSG) treatment protocols for younger adults (AMLSG-HD98A (NCT00146120) and AMLSG 07-04 (NCT00151242)) were analyzed. The characteristics of the patients are given in Table 1 (see also Supplementary Table 1) .
With complete data for FLT3, CEBPA and NPM1 in 146 cases, most cases were well annotated for a large panel of recurrent gene mutations. 5 The incidences were as follows: NPM1 mutations, 59%; FLT3-ITD, 32%; FLT3 tyrosine kinase domain mutations (codons D835 and I836), 12%; CEBPA mutations, 21%; MLL partial tandem duplications, 5%; NRAS mutations, 21%; and WT1 mutations, 14%. 16 Single-nucleotide polymorphism (SNP) microarray-based genotyping analysis DNA was extracted from frozen blood and/or bone marrow samples that had been enriched for leukemic blasts (blast counts were 485% in all analyzed cases). Genotyping was performed on Affymetrix GeneChip human mapping 50 k HindIII (50 k) (n ¼ 117) and 250 k NspI and 250 k StyI (500 k) (n ¼ 69) microarrays according to the manufacturer's protocols (Affymetrix, Santa Clara, CA, USA; for more details see Supplementary Information). Samples from 29 patients were analyzed on both the 50 and 500 k platform (see Supplementary Table 1) . Complete SNP microarray data sets are available at Gene Expression Omnibus (accession number: GSE19101).
Biostatistical evaluation of single-nucleotide polymorphism (SNP) microarray data
To determine the incidence of CNAs in CN-AML, we focused our analysis on the cases hybridized on the high-resolution 500 k platform. Bioinformatic evaluation of CNAs was performed using dChipSNP and circular binary segmentation based on an optimized data normalization procedure as previously described. 8, 17 For loss of heterozygosity analysis of 50 and 500 k data, we used version 2.0 of the Copy Number Analyzer for GeneChip software (CNAG; http://www.genome.umin.jp/ CNAGtop2.html), 18, 19 which implements a hidden Markov model-based algorithm (default setting parameters were chosen). All analyses were performed as paired analysis with diagnostic samples being compared to remission samples derived from the same individual (for more details see Supplementary Information).
Validation of acquired copy number alterations (CNAs) by fluorescence in situ hybridization (FISH) analysis Validation of acquired CNAs was performed using fluorescence in situ hybridization (FISH) as previously described. 20 CNAs in the following chromosomal bands were analyzed (respective clones in parenthesis): 3p14.1 (RP11-522N9), 6q27 (cosmid AF6), 9q21.32 (RP11-439A18, RP11-522I20, RP11-301F14, RP11-361M4), 11p13 (RPCI-11 284G17, RPCI-11 710L2) and 11q23 (YAC 856B9, YAC 785C6).
Statistical analysis
Comparisons of the distributions of clinical and laboratory variables were performed using Fisher's exact test and the Mann-Whitney test for qualitative and quantitative variables, respectively. All tests were two sided. An effect was considered significant if the (adjusted) P-value was p0.05. The analyses were performed using GraphPad Prism 4 (GraphPad Software, La Jolla, CA, USA) and version 2.5.0 of R (available at http://www.r-project.org). 21 
Results
Identification of regions of uniparental disomy (UPD)
When comparing the diagnostic leukemia samples to intraindividual control samples, 11 UPDs were found in 10 of 67 cases (15%) analyzed on the 500 k platform; one of the 10 cases had two UPDs (Table 2) . Notably, all UPDs were 424 Mb in size and were also detected in cases co-analyzed on the 50 k microarray platform. Thus, because of the large size of the UPDs detected in CN-AML the 50 k platform seemed to provide a sufficient resolution to detect all tumor-relevant regions of loss of heterozygosity. In the entire cohort analyzed by the 50 k platform, 14 UPDs were found in 13 of 117 (11%) cases with all UPDs being 429 Mb. In total, 21 UPDs were found in 19 of 157 (12%) cases; two of the 19 cases had two UPDs (Table 2) . UPDs were non-randomly distributed and affected the following chromosomal arms (in the order of decreasing frequency):
and 19q (n ¼ 1). All UPDs represented terminal UPDs (Table 2 and Figure 1 ) as shown by the exemplary cases of AML 143 and AML 159 (Figure 2) , even though statistical analysis might suggest non-terminal aberrations based on either inadequate SNP coverage or data noise toward the chromosomal ends (see also respective remark in Table 2 ).
Identification of copy number alterations (CNAs)
Paired analysis of tumor and matched control revealed 96 acquired CNAs in 33 of 67 cases (49%) analyzed by the 500 k platform (Table 3) . Although in 51% of cases no CNA was detectable (34/67 cases), 16 cases had one, 6 cases had two, and 11 cases had X3 CNAs (range: 0-15 CNAs per case). In general, genomic gains were less frequent (0.25/case) than losses Therapy-induced AML n ¼ 9/155 (6%) Secondary AML a n ¼ 9/155 (6%) (Table 3) . Of the gained regions, 10 harbored at least one gene, whereas in four regions no genes have been described so far (average of 0.86 genes per region). The gain observed in two cases contained a gene: 14q23.1 (PRKCH). Genomic losses were found in 27 of 67 cases (40%) involving 74 regions with deletions in bands 3p14.1-p13, 6q27, 8q23.3, 10q11.21, 11q25, 12p13.2 and 15q21.3 occurring in two cases each. Of the deleted regions, 62 harbored at least one gene, whereas in 12 regions no known genes were located (average of 7.41 genes per region). The minimally altered region (MAR) in 3p14.1-p13 was 4.02 Mb in size (harboring, for example, FOXP1 and RYBP) and monoallelic deletion could be confirmed using FISH (Figure 3 ). The MAR in band 11q25 was 1.07 Mb in size harboring 10 genes, and the MAR in band 12p13 was 1.42 Mb in size including, for example, ETV6. Additional regions affected in two cases with the MAR harboring only one gene included 6q27 (RPS6KA2), 8q23.3 (TRPS1), 10q11.21 (HNRPF) and 15q21.3 (RFXDC2). Table 3 summarizes all CNAs and Figure 1 gives a summary of all aberrations 4100 kb in size.
Comparison of 50 and 500 k microarrays findings in 27 cases, which were initially analyzed using both platforms, showed that by applying the 50 k microarray we could detect 11 acquired CNAs in 27 cases (0.41 CNAs per case) compared with 33 aberrations (1.22 CNAs per case) detected by the 500k microarray. These results show that the application of lowerresolution platforms may miss approximately 60-70% of aberrations. For example, in AML 117 a small 0.26-sized loss in band 11p13 encompassing the WT1 gene was only found with the 500 k microarray (Supplementary Figure 1) . However, larger aberrations, such as the deletions in 3p14.1-p13, could also be detected using the 50 k microarray. Indeed, 50 k analysis revealed an additional case with a deletion 3p (AML 89), which was confirmed by 500 k profiling, thereby allowing to narrow down the MAR in 3p14.1-p13 to a region 2.01 Mb in size that contains seven genes (FOXP1, GPR27, PROK2, EIFE3, SHQ1, RYBP and PPP42R; Figure 3 ).
Furthermore, 50 k analysis showed an additional case (AML 95) with CNAs in bands 11q23.3 and 6q27 encompassing the MLL and MLLT4 locus, respectively (finding confirmed by 500 k analysis). In accordance, AML 132 showed a 0.32 Mb-sized loss in 11q23.3 (MLL locus) and a 0.21 Mb-sized gain in 6q27 (MLLT4 locus), suggesting cryptic insertional rearrangements of the MLL and MLLT4 genes in these cases. FISH analysis confirmed cryptic MLL-MLLT4 fusions in both cases (Supplementary Figure 2 ).
Correlation of single-nucleotide polymorphism (SNP) microarray findings with clinical and molecular genetic data
We found no significant association between clinical variables (age, white blood cell counts, serum lactate dehydrogenase levels and bone marrow blast counts) and the presence of acquired UPDs or CNAs. The presence of UPDs was significantly associated with mutations in NPM1 and CEBPA. All 19 cases with UPDs had a mutation in either NPM1 (n ¼ 13) or CEBPA (n ¼ 6) when compared with 101 out of 131 cases without UPD (Fisher's exact test P ¼ 0.014; Table 2 ). There also seemed to be an association between distinct UPDs and NPM1 and CEBPA mutations: all UPD 6p cases had a NPM1 mutation, 4 of 5 UPD 11p cases had a CEBPA mutation and all UPD 13q cases had a NPM1 mutation (Fisher's exact test P ¼ 0.081, P ¼ 0.007, and P ¼ 0.082, respectively). Consistent with previous reports, 12, 13 all UPD 13q cases showed an FLT3-ITD, resulting in a mutant to wild-type ratio 41.0 in 5 of the 6 cases (determined using DNA fragment analysis). In all, four of the five cases with UPD 11p showed WT1 mutations; the one case with SNP microarray analysis in cytogenetically normal AML L Bullinger et al UPD 19q had a homozygous CEBPA mutation. However, there was no association between acquired CNAs and the presence of NPM1, FLT3-ITD, WT1 and CEBPA mutations.
Correlation of single-nucleotide polymorphism (SNP) microarray findings with clinical outcome
We observed no significant association between clinical outcome and the presence or the number of acquired CNAs (negative data not shown). However, with regard to acquired UPDs, there seemed to be an association between UPD 11p and better outcome (log-rank test P ¼ 0.115), whereas patients with UPD 13q had a significant inferior outcome (P ¼ 0.027; Figure 4 ). The general presence of a UPD was not associated with overall survival (data not shown), neither was the presence of a UPD 6 ( Figure 4 ).
Discussion
By applying high-resolution 500 k SNP microarray analysis to matched diagnostic and remission DNA samples from 157 cases Results of a paired analysis of the 500 k SNP microarray data using dChipSNP and circular binary segmentation based on an optimized data normalization procedure (n ¼ 67).
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with CN-AML, we identified UPDs in 12% of cases and submicroscopic CNAs in 49% of the cases. A previous study in AML that applied lower-resolution SNP microarrays reported higher numbers of UPDs compared with those found in our series. 12 This study, however, did not include intra-individual DNA controls, and is likely overestimating the frequencies of UPDs. On the other hand, studies using low-resolution microarrays may underestimate the prevalence of diseaserelated submicroscopic changes. 12, 22 In accordance with recent studies in hematologic malignancies, 15, 23 in our analyses the 500 k SNP microarray was superior to the 50 k microarray, enabling the detection of lesions o1 Mb (see Supplementary  Figures 1-3 for exemplary cases) . Although recent highresolution SNP microarray profiling detected submicroscopic aberrations in only 8 out of 34 CN-AML cases (in 24% of cases), 24 the algorithm and cutoff used in the study might have been more stringent compared with our analysis, thereby reducing the chance of false-positive results on the expense of not detecting small tumor-relevant aberrations.
Although many of the genomic areas of acquired CNA observed in our study have previously been described as copy number variations (CNVs), [25] [26] [27] paired analysis clearly revealed them to be tumor specific. For example, AML 148 harbored an acquired gain in 22q11.23, in a region for which CNV has been reported (see Database of Genomic Variants; Supplementary  Figure 4) . 25 Especially, the larger genomic gains/losses, that is, all 30 CNAs 4300 kb, have been reported to contain CNVs, which in most cases cover only part of the affected region. However, the facts that known oncogene loci, such as MYC or NRAS can also be affected by CNV in healthy individuals and that all aberrations reported in our study are only present in the leukemia sample show their potential relevance despite the report of CNVs in the respective locations.
For example, the MAR of the cryptic deletion in band 3p14.1-p13 overlaps with a region that we recently described in a cohort of AML cases with complex karyotypes. 28 The RYBP gene, which has been shown to facilitate tumor cell killing, 29 and the FOXP1 gene, involved in a recurring chromosomal translocation t(3;14)(p14;q32) in mucosa-associated lymphoid tissue, 30 represent interesting candidate disease genes in this region.
Similarly, the MAR of the CNA involving band 12p13 includes ETV6 (TEL), a gene involved in translocations in childhood acute lymphoblastic leukemia and affected in rare cases of AML. 10 Although unbalanced abnormalities of 12p are found in approximately 2% and balanced aberrations in o1% of AML cases, 31 in CN-AML single cases with 12p13 deletions encompassing ETV6 have been reported in FISH analyses, 20 array-based comparative genome hybridization 32 and recently also in SNP microarray studies. 33 Consistent with a leukemogenic role of ETV6 in AML, reduced ETV6 protein levels have been detected in one-third of AML cases. 34 With regard to the other CNAs found in two cases, genes that might have a role in tumorigenesis include RPS6KA2 (ribosomal protein S6 kinase, 90kDa, polypeptide 2), which has been implicated in controlling cell growth and differentiation (loss of 6q27), 35 and TRPS1 (trichorhinophalangeal syndrome I) a transcription factor that represses GATA-regulated genes (loss of 8q23.3). 36 Furthermore, in the 11q25 MAR hCAP-D3 seems to be an interesting target that has recently been associated with prostate cancer. 37 In the region gained in two cases, PRKCH represents a potential candidate located in 14q23.1. PRKCH encodes a serine-and threonine-specific protein kinase regulating proliferation through mitogen-activated protein kinase and mitogen-activated protein kinase phosphorylation and subsequent activation of extracellular signal-regulated kinase. 
Even though the remaining CNAs were identified in only single cases, they nonetheless point to disease-relevant genes such as, for example, TET2 (AML 143), which recently has been identified as a novel tumor suppressor inactivated in myeloid neoplasms. 39 ,40 AML 17 represents another interesting case showing a 0.88 Mb-sized deletion in band 9q21.32-q21.33 ( Figure 3) ; the lost segment overlaps with a known MAR on 9q that is associated with the t(8;21)(q22;q22) and with mutations in NPM1 and CEBPA. [41] [42] [43] [44] The heterogeneous nuclear ribonucleoprotein K gene represents a potential candidate gene as its depletion abrogates transcriptional induction of p53 target genes and causes defects in DNA damage-induced cell-cycle checkpoint arrest. 45 The neurotrophic tyrosine kinase receptor type 2 (NTRK2, also known as TRKB) gene, which shows potent oncogenic effects contributing to the metastatic capacity of tumors, 46 is also located in the MAR. However, as one would expect a tumor suppressor rather than an oncogene in this region, heterogeneous nuclear ribonucleoprotein K (HNRPK) might be the relevant candidate gene (Figure 3 ).
Finally, we were able to identify two cases with cryptic rearrangements of bands 6q27 and 11q23 resulting in MLL-MLLT4 (AF6) gene fusions (Supplementary Figure 2) based on associated microdeletions, which have been previously described to occur, for example, in translocations involving MLL and cases harboring a CBFB-MYH11 fusion. 47, 48 Using low-resolution SNP microarray platforms, so far no cryptic MLL translocations have been detected in adult AML. 12 However, recently cryptic NUP98-NSD1 gene fusions could also be detected using SNP microarray analyses in adult AML, 24 and in childhood AML high-resolution screening identified two cases with NUP98-NSD1 gene fusions and two cases with MLL-MLLT4 gene fusions that were not detected by cytogenetic analysis. 49 Thus, these findings indicate the necessity to screen adult CN-AML cases for cryptic MLL-MLLT4 fusions using more sensitive methods such as reverse transcriptase-PCR or FISH.
Similar to previous studies, UPDs were non-randomly distributed and all our UPD 13q cases harbored an FLT3-ITD, four of five UPD 11p cases showed a WT1 mutation and the case with UPD 19 had a CEBPA mutation. 13 Although in the other regions candidate genes are unknown, UPDs might not only result in the duplication of mutated genes, but also lead to duplication of imprinted regions. Of note, all cases with UPD harbored either NPM1 or CEBPA mutations, which are thought to impair hematopoietic differentiation and subsequent apoptosis. Recently, NPM1 has been shown to be haploinsufficient for the control of proper centrosome duplication, resulting in genomic instability with increased risk of cellular transformation. 50 As NPM1 mutations are mainly observed in CN-AML, it was suggested that NPM1 mutants are still effective in controlling centrosome duplication. However, our findings suggest that NPM1 mutations might indeed confer genomic instability, which might result in acquired UPD rather than microscopically visible genomic imbalances. In addition, there seem to be patterns of cooperativity between UPDs and gene mutations. For example, all cases with UPD 13q and four of five cases with UPD 6p had combined NPM1 and FLT3 mutations, and four of five cases with UPD 11p had concomitant CEBPA and WT1 mutations. Notably, the UPD 11p case that lacked a WT1 mutation had no CEBPA mutation, but harbored a NPM1 mutation and an FLT3-ITD. These findings suggest that UPDs preferentially involve genes that confer a proliferative advantage to the leukemic clone.
Furthermore, the presence of UPDs 11p or 13q seemed to be associated with clinical outcome (Figure 4) , an observation of potential clinical relevance that warrants further analysis. Although no correlation was observed with regard to the absence/presence of CNAs, future research will take advantage of the availability of platforms with even higher resolution. Finally, larger cohorts of patients need to be analyzed to confirm the findings presented in this study, and to identify new genetic lesions that will contribute to a better understanding of leukemia biology. 
